Key Takeaways
- Russian drone strike in Romania triggers a "serious escalation" warning from Bucharest and the announcement of a 21st EU sanctions package.
- South Korea’s KOSPI index surges 3.54% to a new record level, driven by a semiconductor supercycle and massive gains in large-cap tech.
- Fed’s Neel Kashkari signals caution, stating that while inflation risks remain persistent, April PCE data does not yet justify an immediate rate hike.
- Innovent Biologics (1801) secures a landmark $10.5 billion deal with Pfizer (PFE) to develop 12 cancer drug trials.
- Mixed European data reveals a 0.2% contraction in Sweden’s Q1 GDP, while German import prices rose more than expected in April.
Geopolitical stability in Eastern Europe faced a fresh crisis on Friday after a Russian drone struck a residential building in the Romanian city of Galați. Romanian President Klaus Iohannis condemned the incident as an "unusual" and "irresponsible escalation," directing the Foreign Ministry to prepare proportionate measures against Moscow. The incident has prompted NATO to bolster its defenses, with the alliance condemning Russia’s "recklessness" after the drone spent approximately four minutes within Romanian territory.
In response to the strike, European Commission President Ursula von der Leyen announced that the bloc is preparing its 21st package of sanctions against Russia. French Foreign Minister Jean-Noël Barrot also confirmed that the Russian ambassador was summoned on Friday. While the U.S.-made MEROPS anti-drone system was operational in the region, Romanian officials noted it was not deployed in the urban setting due to safety concerns for civilians.
In financial markets, South Korea’s benchmark KOSPI index rose 3.54%, closing at a new record high. The rally has been fueled by a massive surge in the semiconductor sector, with Samsung Electronics (005930) and SK Hynix (000660) leading the charge. Analysts note that the KOSPI has now doubled in value during 2026 alone, as global investors pivot toward Asian tech exporters amid a burgeoning AI-driven memory supercycle.
Monetary policy remains a central focus for investors as Minneapolis Fed President Neel Kashkari addressed the latest inflation data. Kashkari stated that the April PCE inflation data—which saw headline inflation hit a three-year high of 3.8%—does not justify an immediate conclusion that rate hikes are necessary. However, he warned that inflation risks continue to require close attention, noting the danger of expectations becoming "unanchored" across different economic scenarios.
In the healthcare sector, Innovent Biologics (1801) signed a massive $10.5 billion collaboration deal with Pfizer (PFE). The agreement involves 12 cancer drug trials, with Innovent receiving an upfront payment of $650 million. The deal highlights the growing global interest in China’s biotech pipeline and sent Innovent’s shares soaring in Friday’s trading session.
Economic data from Europe provided a somber contrast to the rally in Asia. Sweden’s GDP contracted by 0.2% in the first quarter of 2026, falling short of market expectations. Additionally, Sweden’s retail sales were flat in March, suggesting tepid private spending. Conversely, Germany’s Import Price Index rose 1.2% in April, slightly exceeding estimates and signaling persistent pipeline price pressures in the Eurozone’s largest economy.
In the corporate landscape, Samsung Electronics (005930) continues to face internal friction as its minority union announced plans to challenge a recent wage deal in court. Meanwhile, Barclays lowered its price target for hospitality group Whitbread (WTB) to 2100p from 2500p, reflecting a more cautious outlook for the UK leisure sector. The broader market remains sensitive to geopolitical developments, particularly as Pakistan’s Foreign Minister meets with U.S. Secretary of State Marco Rubio to mediate the ongoing conflict between the U.S. and Iran.
Ed Liston is a senior contributing editor at TheStockMarketWatch.com. An active market watcher and investor, Ed guides an independent team of experienced analysts and writes for multiple stock trader publications.